6,119 Shares in Axsome Therapeutics, Inc. (NASDAQ:AXSM) Acquired by Fox Run Management L.L.C.

Fox Run Management L.L.C. acquired a new position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm acquired 6,119 shares of the company’s stock, valued at approximately $518,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Iron Triangle Partners LP purchased a new position in shares of Axsome Therapeutics during the third quarter valued at $22,671,000. Principal Financial Group Inc. grew its holdings in Axsome Therapeutics by 6,002.7% during the 4th quarter. Principal Financial Group Inc. now owns 207,065 shares of the company’s stock worth $17,520,000 after acquiring an additional 203,672 shares in the last quarter. FMR LLC increased its position in Axsome Therapeutics by 20.6% during the 3rd quarter. FMR LLC now owns 1,088,087 shares of the company’s stock valued at $97,786,000 after purchasing an additional 185,951 shares during the period. Raymond James Financial Inc. bought a new stake in shares of Axsome Therapeutics in the 4th quarter valued at about $14,771,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Axsome Therapeutics in the 4th quarter worth approximately $6,219,000. 81.49% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on AXSM shares. Deutsche Bank Aktiengesellschaft started coverage on shares of Axsome Therapeutics in a report on Tuesday, February 11th. They set a “buy” rating and a $176.00 price objective on the stock. Wells Fargo & Company lifted their price target on Axsome Therapeutics from $140.00 to $160.00 and gave the company an “overweight” rating in a report on Wednesday, February 12th. Bank of America upped their price objective on Axsome Therapeutics from $143.00 to $167.00 and gave the stock a “buy” rating in a research note on Tuesday, February 11th. Needham & Company LLC reiterated a “buy” rating and issued a $153.00 target price on shares of Axsome Therapeutics in a research note on Monday, March 3rd. Finally, Morgan Stanley increased their price target on shares of Axsome Therapeutics from $125.00 to $190.00 and gave the company an “overweight” rating in a research report on Thursday, February 27th. One research analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company. According to MarketBeat, Axsome Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $167.36.

Insider Activity

In other Axsome Therapeutics news, CFO Nick Pizzie sold 3,000 shares of Axsome Therapeutics stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $131.07, for a total transaction of $393,210.00. Following the completion of the transaction, the chief financial officer now owns 42,187 shares in the company, valued at approximately $5,529,450.09. This trade represents a 6.64 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 22.40% of the company’s stock.

Axsome Therapeutics Stock Performance

Shares of AXSM stock opened at $120.36 on Wednesday. The business has a fifty day moving average of $118.07 and a 200 day moving average of $100.65. Axsome Therapeutics, Inc. has a 1 year low of $64.11 and a 1 year high of $139.13. The company has a debt-to-equity ratio of 3.22, a current ratio of 2.11 and a quick ratio of 2.04. The firm has a market capitalization of $5.87 billion, a price-to-earnings ratio of -20.09 and a beta of 1.00.

Axsome Therapeutics (NASDAQ:AXSM) last released its earnings results on Tuesday, February 18th. The company reported ($0.96) EPS for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.01. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%. The firm had revenue of $118.77 million during the quarter, compared to the consensus estimate of $117.83 million. As a group, research analysts expect that Axsome Therapeutics, Inc. will post -2.79 earnings per share for the current year.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.